FDA Clarifies When Wellness Apps and Wearables Fall Under Medical Device Regulation

The FDA applies a risk-based approach to digital health technologies. It generally exercises enforcement discretion for low-risk products intended for general wellness such as apps or wearables that promote physical activity, stress management or sleep. Such tools avoid regulation as medical devices when they steer clear of disease-specific claims. This stance stems from guidance documents that give developers clearer boundaries.

What this means

The distinction separates everyday tracking tools from devices that make specific medical claims. Apps and wearables for activity, sleep or stress often stay outside premarket review. Developers gain concrete examples they can use to evaluate their own products. Higher-risk items linked to disease diagnosis or treatment remain subject to standard FDA processes.

Key takeaways

• FDA enforcement discretion applies to low-risk general wellness products intended solely for physical fitness, weight management or relaxation without disease claims, according to its 2016 policy. [2]
• Mobile apps that track general health indicators and do not diagnose or treat specific conditions fall outside premarket review per the 2019 guidance. [3]
• The Digital Health Center of Excellence coordinates regulatory approaches and offers clarity for developers on wellness and prevention tools. [1]
• Intended use and exact claims determine regulatory status rather than the underlying technology platform. [2][3]
• Clear avoidance of disease treatment or prevention language keeps products in the general wellness category. [2]

The FDA issued its general wellness policy on July 29, 2016. It states that products promoting general wellness without references to diseases, disorders or conditions are not regulated as medical devices. [2]

The agency followed with updated software guidance on September 27, 2019. That document draws a line between wellness functions and those that meet the definition of a medical device. [3]

Its Digital Health Center of Excellence plays an ongoing role in these efforts. The center works to align policy and reduce uncertainty for companies creating preventive tools. [1]

Criteria focus on two main questions. First, is the product intended for general wellness? Second, does it make any claims about diagnosing, mitigating, treating, curing or preventing a disease? Products that answer no to the second question usually stay in the low-risk lane.

Claims matter more than the hardware or code itself. A wearable that says it helps users relax falls under enforcement discretion. The same device claiming to treat clinical anxiety would trigger regulation. The FDA evaluates the labeling, marketing materials and stated intended use together.

This framework lets developers perform their own assessments. Many consumer apps for step counting, menstrual cycle tracking or basic stress relief can proceed without formal FDA submission. The guidance stops short of addressing every detail. Separate rules cover data security, privacy and clinical evidence.

Limitations

Guidance applies only to low-risk products. Any claims related to disease diagnosis, cure, mitigation, treatment or prevention trigger full device regulation. It does not cover data privacy, cybersecurity, or clinical validation requirements addressed in separate FDA or other agency policies.

Sources / References

1. U.S. Food and Drug Administration. Digital Health Center of Excellence. https://www.fda.gov/medical-devices/digital-health-center-excellence

2. U.S. Food and Drug Administration. General Wellness: Policy for Low Risk Devices. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices

3. U.S. Food and Drug Administration. Policy for Device Software Functions and Mobile Medical Applications. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications